Navigation Links
Landmark survey reveals that most women who are done having children do not discuss their options with their OB/GYNs

Hollywood, FL, Nov. 7, 2011 A recent first-of-its-kind survey of 1,006 mothers in the U.S. showed that more than 75 percent of women reported being done having children, but only 24 percent discussed this decision with their OB/GYNs. Without these important patient-physician conversations taking place, the survey found that women remain largely unaware of their permanent birth control options. In particular, the survey showed low awareness for non-surgical permanent birth control methods like the Essure procedure, which has been available in the U.S. since 2002 and is the most effective form of permanent birth control available.*

"I was surprised that so many women who report being done having children are not talking to their healthcare providers about their decision," said Dr. Linda Bradley, President of AAGL and a practicing OB/GYN. "Permanent birth control can be an ideal solution for couples who are content with their families and want to avoid future unplanned pregnancies. However, most women are unaware of permanent options that do not require surgery, revealing a huge opportunity for us, as physicians, to educate our patients."

Patients Don't Know About the Non-Surgical Permanent Birth Control Methods

Nearly 90 percent of women surveyed knew about vasectomy and tubal ligation, as these are typically the first options most couples consider when they are done having children. However, only 12 percent were aware of non-surgical, minimally invasive solutions such as Essure.

"Although non-surgical permanent birth control for women has been available for nearly a decade, I often find female patients are surprised to learn that they don't have to get a tubal ligation or ask their husbands to go for a vasectomy," said Dr. Bradley. "The Essure non-surgical permanent birth control procedure offers women the option of no incisions, no hormones, no general anesthesia and no slowing down to recover."

Women Want Effectiveness, But They're Sticking with the Familiar

Though women surveyed said that effectiveness was one of the most important factors when considering permanent birth control, many women who are done having children are continuing to rely on less effective methods like condoms, which have a 15 percent commercial failure rate,1 or the Pill, which has an 8 percent commercial failure rate.1

In comparison, a 10-year global study being released at the AAGL meeting explores the data of the commercial use of Essure by approximately 500,000 women and tracks closely with Essure's clinical effectiveness rate of 99.8 percent.*

About the Survey and Methodology

The online survey was conducted by Harris Interactive among 1,006 women age 28-48 who have at least one child and are married or in a committed relationship. Respondents for this survey were selected from among those who have agreed to participate in Harris Interactive surveys. Because the sample is based on those who have agreed to participate in the Harris Interactive online research panel, no estimates of theoretical sampling error can be calculated. Online interviews took place between August 30 and September 6, 2011. Results were weighted for race/ethnicity, education, household income, region and employment status. This survey was commissioned by HealthyWomen and supported by an educational grant from Conceptus, Inc.

About the Essure Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around and through the inserts to prevent sperm from reaching the egg. Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and that the fallopian tubes are fully blocked, allowing the patient to rely upon Essure for permanent birth control.

The Essure procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.

Contact: Traci Tournoux
HealthStar PR

Related medicine news :

1. New edition of landmark stroke textbook
2. California to Examine Health Impacts of Landmark Cap-and-Trade Program
3. Foodborne Illness Costs U.S. $152 Billion Annually, Landmark Report Estimates
4. Landmark Legal Foundation to File Suit to Stop Presidents Health Plan if Slaughter Rule is Used
5. China's Forbidden City Leads Landmark Climate Action for Earth Hour
6. Endometriosis Foundation of America to Present Landmark Scientific Symposium in NYC
7. Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
8. Landmark report reveals massive global cost of Alzheimers: 1 percent of global GDP -- and growing
9. Feeling included -- kids with disabilities have their say in landmark study
10. Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma
11. UT Southwestern pediatricians launch landmark childrens health study
Post Your Comments:
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Beddit® has launched ... Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that rates ... how well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development and ... of its current state of the art research, development and manufacturing facility outside ... its manufacturing capacity as well as to support its clients’ growing research and ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... -- --> --> ... das Patent über eine neue Hepatitis-B-Behandlung, welches sie gemeinsam ... Enyo Pharma vergeben haben. Im Rahmen ... von Edelris gemeinsam mit seinen Partnern Inserm und Poxel ... identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die zu ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
Breaking Medicine Technology: